Inge-Marie Obdeijn

1.4k citations

18 papers · 835 indexed · h-index 13

Cancer Research top 5%
Pathology and Forensic Medicine top 5%
Genetics top 10%
Oncology top 10%
Radiology, Nuclear Medicine and Imaging top 5%

Co-authors: Madeleine M.A. Tilanus‐Linthorst Cecile T.M. Brekelmans M. Menke-Pluymers A.Y. de Kanter Caroline Seynaeve Vibeke Kuenen‐Boumeester Theodorus van der Kwast C. Crépin
Topics: BRCA gene mutations in cancer (13 papers)Global Cancer Incidence and Screening (7 papers)Breast Cancer Treatment Studies (6 papers)
Cited by: Cancer Research Pathology and Forensic Medicine Genetics
Journals: Journal of Clinical Oncology JNCI Journal of the National Cancer Institute Clinical Cancer Research
Partner nations: Netherlands United States Australia

In The Last Decade

Inge-Marie Obdeijn

17 papers receiving 811 citations

Peers

Countries citing papers authored by Inge-Marie Obdeijn

Since Specialization

Citations

This map shows the geographic impact of Inge-Marie Obdeijn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inge-Marie Obdeijn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inge-Marie Obdeijn more than expected).

Fields of papers citing papers by Inge-Marie Obdeijn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inge-Marie Obdeijn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inge-Marie Obdeijn. The network helps show where Inge-Marie Obdeijn may publish in the future.

Co-authorship network of co-authors of Inge-Marie Obdeijn

This figure shows the co-authorship network connecting the top 25 collaborators of Inge-Marie Obdeijn. A scholar is included among the top collaborators of Inge-Marie Obdeijn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inge-Marie Obdeijn. Inge-Marie Obdeijn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study 2022 ·Breast Cancer Research and Treatment ·(unknown),(unknown),B.A.M. Heemskerk-Gerritsen,Inge-Marie Obdeijn,Linetta B. Koppert,Claudette E. Loo,Rob A.�E.�M. Tollenaar,Margreet G.E.M. Ausems,Irma van de Beek,(unknown),Maaike de Boer,(unknown),C. Marleen Kets,Matti A. Rookus,(unknown),Marjanka K. Schmidt,Agnes Jager,Maartje J. Hooning	0
2	Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial risk 2021 ·The Breast ·H. Amarens Geuzinge,Eveline A.M. Heijnsdijk,Inge-Marie Obdeijn,Harry J. de Koning,Madeleine M.A. Tilanus‐Linthorst	11
3	The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers 2020 ·Breast Cancer Research and Treatment ·Inge-Marie Obdeijn,Ritse M. Mann,(unknown),Marc B. I. Lobbes,(unknown),Carolien H. M. van Deurzen,Geertruida H. de Bock,Maartje J. Hooning	9
4	Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk 2020 ·JAMA Oncology ·H. Amarens Geuzinge,Inge-Marie Obdeijn,Emiel J. Rutgers,Sepideh Saadatmand,Ritse M. Mann,Jan C. Oosterwijk,Rob A.�E.�M. Tollenaar,Diderick B. W. de Roy van Zuidewijn,Marc B. I. Lobbes,Martijne van ’t Riet,Maartje J. Hooning,Margreet G.E.M. Ausems,Claudette E. Loo,Jelle Wesseling,Ernest J. T. Luiten,Harmien M. Zonderland,Cees Verhoef,Eveline A.M. Heijnsdijk,Madeleine M.A. Tilanus‐Linthorst,Harry J. de Koning,(unknown)	34
5	Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? – A cost-effectiveness analysis 2019 ·The Breast ·(unknown),Marcel J. W. Greuter,Inge-Marie Obdeijn,Jan C. Oosterwijk,Talitha Feenstra,Nehmat Houssami,Geertruida H. de Bock	9
6	Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using models 2016 ·European Journal of Cancer ·Inge-Marie Obdeijn,Eveline A.M. Heijnsdijk,M. G. Myriam Hunink,Madeleine M.A. Tilanus‐Linthorst,Harry J. de Koning	15
7	Benefits of preoperative MRI in breast cancer surgery studied in a large population-based cancer registry 2015 ·British journal of surgery ·Elvira L. Vos,Adri C. Voogd,Cornelis Verhoef,Sabine Siesling,Inge-Marie Obdeijn,Linetta B. Koppert	28
8	Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy 2014 ·Cancer Biology & Therapy ·(unknown),B.A.M. Heemskerk-Gerritsen,Rob B. van der Luijt,Inge-Marie Obdeijn,Madeleine M.A. Tilanus‐Linthorst,Cornelis Verhoef,Marjanka K. Schmidt,Linetta B. Koppert,Maartje J. Hooning,Caroline Seynaeve	5
9	Should we screen BRCA1 mutation carriers only with MRI? A multicenter study 2014 ·Breast Cancer Research and Treatment ·Inge-Marie Obdeijn,(unknown),Ritse M. Mann,Maartje J. Hooning,M. G. Myriam Hunink,Madeleine M.A. Tilanus‐Linthorst	46
10	Preoperative prediction of cosmetic results in breast conserving surgery 2014 ·Journal of Surgical Oncology ·Elvira L. Vos,Anton H. J. Koning,Inge-Marie Obdeijn,(unknown),Cornelis Verhoef,Peter J. van der Spek,Marian B. E. Menke‐Pluijmers,Linetta B. Koppert	33
11	Cost-Effectiveness of Screening Women With Familial Risk for Breast Cancer With Magnetic Resonance Imaging 2013 ·JNCI Journal of the National Cancer Institute ·Sepideh Saadatmand,Madeleine M.A. Tilanus‐Linthorst,Emiel J. Rutgers,Nicoline Hoogerbrugge,Jan C. Oosterwijk,Rob A.�E.�M. Tollenaar,Maartje J. Hooning,Claudette E. Loo,Inge-Marie Obdeijn,Eveline A.M. Heijnsdijk,Harry J. de Koning	54
12	Preoperative Breast MRI Can Reduce the Rate of Tumor-Positive Resection Margins and Reoperations in Patients Undergoing Breast-Conserving Surgery 2013 ·American Journal of Roentgenology ·Inge-Marie Obdeijn,Madeleine M.A. Tilanus‐Linthorst,Sandra Spronk,Carolien H. M. van Deurzen,Cecile de Monyé,M. G. Myriam Hunink,(unknown)	51
13	Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial 2012 ·BMC Cancer ·Sepideh Saadatmand,Emiel J. Rutgers,(unknown),(unknown),(unknown),(unknown),(unknown),Linetta B. Koppert,Eveline A.M. Heijnsdijk,Caroline Seynaeve,Cees Verhoef,Jan C. Oosterwijk,Inge-Marie Obdeijn,Harry J. de Koning,Madeleine M.A. Tilanus‐Linthorst	15
14	An ultrasound cylindrical phased array for deep heating in the breast: theoretical design using heterogeneous models 2009 ·Physics in Medicine and Biology ·Jurriaan F. Bakker,Margarethus M. Paulides,Inge-Marie Obdeijn,Gerard C. van Rhoon,Koen W. A. van Dongen	36
15	BRCA1 Mutation and Young Age Predict Fast Breast Cancer Growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening Trials 2007 ·Clinical Cancer Research ·Madeleine M.A. Tilanus‐Linthorst,Inge-Marie Obdeijn,Wim C.J. Hop,Petrina A. Causer,Martin O. Leach,Ellen Warner,Linda Pointon,Kimberley Hill,Jan G.M. Klijn,Ruth Warren,Fiona J. Gilbert	73
16	Hereditary breast cancer growth rates and its impact on screening policy 2005 ·European Journal of Cancer ·Madeleine M.A. Tilanus‐Linthorst,Mieke Kriege,C. Boetes,Wim C.J. Hop,Inge-Marie Obdeijn,Jan C. Oosterwijk,Hans Peterse,Harmine M. Zonderland,Sybren Meijer,Alexander M.M. Eggermont,Harry J. de Koning,Jan G.M. Klijn,Cecile T.M. Brekelmans	58
17	Ultrasound-guided fine needle aspiration cytology of axillary lymph nodes in breast cancer patients. A preoperative staging procedure 2002 ·European Journal of Cancer ·Vibeke Kuenen‐Boumeester,M. Menke-Pluymers,A.Y. de Kanter,Inge-Marie Obdeijn,(unknown),Theodorus van der Kwast	125
18	Effectiveness of Breast Cancer Surveillance in BRCA1/2 Gene Mutation Carriers and Women With High Familial Risk 2001 ·Journal of Clinical Oncology ·Cecile T.M. Brekelmans,Caroline Seynaeve,C.C.M. Bartels,Madeleine M.A. Tilanus‐Linthorst,E.J. Meijers-Heijboer,C. Crépin,A.N. van Geel,Marcel N. Menke,L.C. Verhoog,A. van den Ouweland,Inge-Marie Obdeijn,J.G.M. Klijn	233

About Inge-Marie Obdeijn

Inge-Marie Obdeijn is a scholar working on Cancer Research, Genetics and Pathology and Forensic Medicine, having authored 18 papers that have together received 835 indexed citations. Recurring topics across this work include BRCA gene mutations in cancer (13 papers), Global Cancer Incidence and Screening (7 papers) and Breast Cancer Treatment Studies (6 papers). The work is most often cited by research in Cancer Research (413 citations), Pathology and Forensic Medicine (359 citations) and Genetics (324 citations). Inge-Marie Obdeijn has collaborated with scholars based in Netherlands, United States and Australia. Frequent co-authors include Madeleine M.A. Tilanus‐Linthorst, Cecile T.M. Brekelmans, M. Menke-Pluymers, A.Y. de Kanter, Caroline Seynaeve, Vibeke Kuenen‐Boumeester, Theodorus van der Kwast, C. Crépin, A.N. van Geel and Marcel N. Menke. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact